Monoclonal antibodies to mycosphaerella species
CA 2045875 C · Owner: Novartis Ag · Inventors: Petersen, Frank P.; Clymer, Mark D.; Grothaus, Gary D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to monoclonal antibodies that react specifically with members of the, genus Mycosphaerella and hybridomas that produce such antibodies. The invention is, further directed to a method for making a hybridoma cell line that produces monoclonal, antibodies that react specifically with at least one species of Mycosphaerella, and a, method of obtaining monoclonal antibodies therefrom. Methods and kits for diagnosing, Mycosphaerella infections in plant material using such monoclonal antibodies are also, within the scope of the invention.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 27, 1991 and granted November 12, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 27, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 27, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.